BLA1 M005A
Alternative Names: BLA1-M005ALatest Information Update: 28 May 2023
At a glance
- Originator Sichuan Baili Pharmaceutical
- Developer Sichuan Baili Pharmaceutical; SystImmune
- Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Nasopharyngeal cancer
Most Recent Events
- 28 May 2023 No recent reports of development identified for research development in Nasopharyngeal-cancer in China (Parenteral)
- 28 May 2023 No recent reports of development identified for research development in Nasopharyngeal-cancer in USA (Parenteral)
- 01 Apr 2019 Early research in Nasopharyngeal cancer in China and USA (Parenteral) before April 2019 (Sichuan Baili Pharmaceutical pipeline, April 2019)